The life sciences investment space has been largely immune to the negative impacts of the COVID-19 pandemic. Growth in the pharmaceutical, biotechnology and medical device industries has led to increased interest from private equity investors, many of which are new to the life sciences market.

In this video we address:

• Three areas ripe for private equity investment in the life sciences arena
• Sector-specific due diligence concerns investors should address
• Opportunities for ROI when investing in life sciences and life sciences adjacent companies